Skip to main content
SpringerLink
Log in

Die radikale Prostatektomie als Teil eines multimodalen Konzepts für Patienten mit Prostatakarzinom- und Knochenmetastasen bei der Erstdiagnose

Radical prostatectomy as part of a multimodal concept for patients with prostate cancer and bone metastases at initial diagnosis

  • Leitthema
  • Published:
Der Urologe Aims and scope Submit manuscript

Zusammenfassung

Bei Patienten mit Prostatakarzinom und synchronen Knochenmetastasen stellt die chirurgische Entfernung des Primarius eine experimentelle Therapie dar. Im Beitrag beleuchten wir eine Rationale zu diesem Vorgehen.

Abstract

In patients with metastatic prostate cancer presenting with synchronous bone metastases, the surgical removal of the primary is an experimental treatment approach. In the following article, we evaluate the rationale for this approach.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Notes

  1. http://www.cancer.org/research/cancerfactsstatistics/cancerfactsandfigures2017.

  2. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, Kurzversion 4.0, 2016, AWMF Registernummer: 043/022OL, http://leitlinienprogramm-onkologie.de/Prostatakarzinom.58.0.html (Zugriff am: 01.02.2017).

Literatur

  1. Wu JN, Fisch KN, Evans CP (2014) No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period. Cancer 120:818–823

    Article  CAS  PubMed  Google Scholar 

  2. Gandaglia G, Bray F, Cooperberg MR, Karnes RJ, Leveridge MJ, Moretti K et al (2016) Reply from Authors re: Julia Verne, Luke Hounsome, Roger Kockelbergh, Jem Rashbass. Improving outcomes from prostate cancer: unlocking the treasure trove of information in cancer registries. Eur Urol 2016;69:1013–4. Eur Urol 69(6):1015

    Article  PubMed  Google Scholar 

  3. Gandaglia G, Bray F, Cooperberg MR, Karnes RJ, Leveridge MJ, Moretti K et al (2016) Prostate cancer registries: current status and future directions. Eur Urol 69(6):998–1012

    Article  PubMed  Google Scholar 

  4. James ND, Spears MR, Clarke NW, Dearnaley DP, De Bono JS, Gale J et al (2015) Survival with newly diagnosed metastatic prostate cancer in the „Docetaxel Era“: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019). Eur Urol 67(6):1028–1038

    Article  PubMed  Google Scholar 

  5. Attard G, Sydes MR, Mason MD, Clarke NW, Aebersold D, de Bono JS et al (2014) Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial. Eur Urol 66(5):799–802

    Article  CAS  PubMed  Google Scholar 

  6. James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR et al (2016) Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387(10024):1163–1177

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Parker CC, Sydes MR, Mason MD, Clarke NW, Aebersold D, de Bono JS et al (2013) Prostate radiotherapy for men with metastatic disease: a new comparison in the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) trial. BJU Int 111(5):697–699

    Article  CAS  PubMed  Google Scholar 

  8. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P et al (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368(2):138–148

    Article  CAS  PubMed  Google Scholar 

  9. Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T et al (2016) EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. doi:10.1016/j.eururo.2016.08.002

    Google Scholar 

  10. Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M et al (2015) EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 67(5):913–924

    Article  PubMed  Google Scholar 

  11. Engel J, Bastian PJ, Baur H, Beer V, Chaussy C, Gschwend JE et al (2010) Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. Eur Urol 57(5):754–761

    Article  PubMed  Google Scholar 

  12. Haffner MC, Mosbruger T, Esopi DM, Fedor H, Heaphy CM, Walker DA et al (2013) Tracking the clonal origin of lethal prostate cancer. J Clin Invest 123(11):4918–4922

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JM, Papaemmanuil E et al (2015) The evolutionary history of lethal metastatic prostate cancer. Nature 520(7547):353–357

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Gratzke C, Engel J, Stief CG (2014) Role of radical prostatectomy in metastatic prostate cancer: data from the Munich Cancer Registry. Eur Urol 66:602–603

    Article  PubMed  Google Scholar 

  15. Sooriakumaran P, Karnes J, Stief C (2016) A multi-institutional analysis of perioperative outcomes in 106 men who underwent radical prostatectomy for distant metastatic prostate cancer at presentation. Eur Urol 69:788–794

    Article  PubMed  Google Scholar 

  16. Lellig K, Gratzke C, Kretschmer A et al (2015) Final pathohistology after radical prostatectomy in patinets ellegible for active surveillance. World J Urol 33:917–922

    Article  PubMed  Google Scholar 

  17. Herlemann A, Stief C (2016) Aktive Überwachung beim Niedrig-Risiko-Prostatakarzinom. Urologe 55:269–281

    Article  PubMed  Google Scholar 

  18. Van der Poel H, Klotz L, Andriole G et al (2015) Role of active surveillance and focal therapy in low and intermediate risk prostate cancer. W J Urol 33:907–916

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Urologische Klinik des Klinikums der Universität München, Ludwig-Maximilians-Universität, Marchioninistr. 15, 81377, München, Deutschland

    A. Spek, A. Herlemann, C. Gratzke &  C. G. Stief MD, PhD

Authors
  1. A. Spek
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Herlemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Gratzke
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. G. Stief MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. G. Stief MD, PhD.

Ethics declarations

Interessenkonflikt

A. Spek, A. Herlemann, C. Gratzke und C. Stief geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Spek, A., Herlemann, A., Gratzke, C. et al. Die radikale Prostatektomie als Teil eines multimodalen Konzepts für Patienten mit Prostatakarzinom- und Knochenmetastasen bei der Erstdiagnose. Urologe 56, 595–598 (2017). https://doi.org/10.1007/s00120-017-0366-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-017-0366-8

Schlüsselwörter

Keywords

Search

Navigation